Orient Europharma Co Ltd (4120) — Capital Reinvestment Ratio
Orient Europharma Co Ltd (4120) has a Capital Reinvestment Ratio of 2.68x as of June 2025, meaning it reinvests 3% of its operating cash flow (NT$33.25 Million) in capital expenditures (NT$89.03 Million). See Orient Europharma Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Orient Europharma Co Ltd Capital Reinvestment Ratio (2015–2023)
This chart tracks Orient Europharma Co Ltd's Capital Reinvestment Ratio across 8 annual periods. Check Orient Europharma Co Ltd (4120) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Orient Europharma Co Ltd (2015–2023)
Year-by-year Capital Reinvestment Ratio for Orient Europharma Co Ltd from 2015 to 2023. For live market cap and broader valuation context, see 4120 market cap overview.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.56x | NT$64.67 Million | NT$100.70 Million | ▼ -92.3% |
| 2021 | 20.13x | NT$77.65 Million | NT$1.56 Billion | ▲ +5161.6% |
| 2020 | 0.38x | NT$608.55 Million | NT$232.78 Million | ▼ -30.4% |
| 2019 | 0.55x | NT$227.37 Million | NT$124.98 Million | ▼ -36.9% |
| 2018 | 0.87x | NT$231.31 Million | NT$201.61 Million | ▲ +42.5% |
| 2017 | 0.61x | NT$601.08 Million | NT$367.66 Million | ▼ -69.7% |
| 2016 | 2.02x | NT$111.24 Million | NT$224.81 Million | ▲ +467.0% |
| 2015 | 0.36x | NT$643.97 Million | NT$229.54 Million | — |